https://www.selleckchem.com/products/sn-38.html
with HCC and might be a potential biomarker for prognosis of HCC. Overexpression of NOP58 is negatively correlated with overall survival in patients with HCC and might be a potential biomarker for prognosis of HCC. STRIVE was a 4-year, multicenter, observational, open-label, single-arm study of natalizumab treatment in anti-JC virus antibody-negative (JCV-negative) relapsing-remitting multiple sclerosis (RRMS) patients with disease duration ≤ 3years. The objective of STRIVE was to examine no evidence of disease activity (NEDA) status and
Like
Comment
Share
